| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-410X.2003.04407.X |
| P698 | PubMed publication ID | 14983964 |
| P50 | author | Anssi Auvinen | Q47337660 |
| P2093 | author name string | Ciatto S | |
| Zappa M | |||
| Paez A | |||
| Otto SJ | |||
| Villers A | |||
| P2860 | cites work | Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data | Q30655766 |
| Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam | Q39547331 | ||
| Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial | Q39589717 | ||
| Survey of the rate of PSA testing in general practice | Q40688697 | ||
| The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States | Q46839515 | ||
| Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists | Q47801816 | ||
| Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer | Q50717991 | ||
| The accuracy of primary care patients' self-reports of prostate-specific antigen testing. | Q51960895 | ||
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 97-100 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. | |
| P478 | volume | 92 Suppl 2 |
| Q28286011 | Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial |
| Q33781171 | Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial |
| Q40123788 | Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study |
| Q44740163 | Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer |
| Q34326169 | Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms |
| Q50878494 | High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. |
| Q39180719 | Impact of cause of death adjudication on the results of the European prostate cancer screening trial. |
| Q46371842 | Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. |
| Q43409612 | PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer |
| Q44328071 | Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007. |
| Q26781093 | Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis |
| Q34261229 | Prostate-cancer mortality at 11 years of follow-up |
| Q37258845 | Rationale for statins in the chemoprevention of prostate cancer. |
| Q24201690 | Screening for prostate cancer |
| Q24245476 | Screening for prostate cancer |
| Q36407365 | Serum total and HDL cholesterol and risk of prostate cancer |
| Q37187362 | Statins and prostate cancer prevention: where we are now, and future directions. |
| Q45344726 | The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study |
| Q38800777 | The current evidence on statin use and prostate cancer prevention: are we there yet? |
| Q47358352 | The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. |
| Q37777325 | The implementation of screening for prostate cancer |
| Q35234770 | What do the screening trials really tell us and where do we go from here? |
| Q51302170 | What explains the differences between centres in the European screening trial? A simulation study. |
| Q79894708 | [Prevalence and clinical meaning of focal and incidental prostate cancers] |
Search more.